Claims

1. A pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), and/or TIGIT for use in the treatment of acute myeloid leukemia (AML), wherein the inhibitor is an antibody which specifically binds to CD112, CD155 or TIGIT, and wherein the pharmaceutical composition further comprises a bispecific single chain Fv (scFv) antibody construct that engages T cells and comprises a CD3epsilon binding domain and a further binding domain targeting a surface molecule selected from the group consisting of CD33, CD19 and Flt3.

2. The pharmaceutical composition for use according to claim 1, wherein said inhibitor against CD112 inhibits the interaction between CD112 and TIGIT or wherein said inhibitor against CD155 inhibits the interaction between CD155 and TIGIT, or wherein said inhibitor against TIGIT inhibits the interaction between TIGIT and CD112, or wherein said inhibitor against TIGIT inhibits the interaction between TIGIT and CD155.

3. The pharmaceutical composition for use of according to claim 1, wherein said inhibitor against CD112 modulates intracellular signaling of CD112.

4. The pharmaceutical composition for use of according to claim 1, wherein said inhibitor against CD155 modulates intracellular signaling of CD155.

5. The pharmaceutical composition for use of according to claim 1, wherein said inhibitor against TIGIT modulates intracellular signaling of TIGIT.

6. The pharmaceutical composition for use of according to claim 1, wherein the antibody construct that engages T cells and comprises a CD3epsilon binding domain and a further binding domain targeting a surface molecule selected from the group consisting of CD33, CD19 and Flt3 is selected from the molecules depicted in SEQ ID Nos.: 15 to 37.